Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Financing › Details

Lytix Biopharma–SEVERAL: investment, 201312 capital increase NOK50m


Period Period 2013-12-04
  Successor Lytix Biopharma–SEVERAL: investment, 201512 capital increase NOK80m w 224.2k new shares at NOK350/share to existent + new shareholders
Organisations Money taker Lytix Biopharma AS
  Money source SEVERAL
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 investment banking

Lytix Biopharma AS. (12/5/13). "Press Release: NOK50 Million Subscribed in Lytix Biopharma".

Lytix Biopharma AS has completed a successful issue that was subscribed shares of over 50 million NOK. It was signed for in total 71,670 shares at a subscription price of NOK 700 per share. The Company will, after the capital increase is registered in the 'Business Register', have 207 shareholders.

CEO Unni Hjelmaas is delighted with Lytix Biopharma now having secured funding for the implementation of the company's exciting plans within infection and cancer research through 2014.

"We are pleased with the interest the company has been shown in the challenging capital market", says the chairman Knut Eidissen.

In the issue the following insiders have been allocated shares:
Picasso Kapital AS, controlled by chairman Knut Eidissen, 5760 shares
Steinar Hoeg, Director, 1,200 shares
Unni Hjelmaas, CEO 143 shares

Fazenda Securities has been the advisor and lead facilitator of this issue, and Sparebank1 Market has been co-facilitator.

Lytix Biopharma's board considers listing the company on the Oslo Stock Exchange, including the optimal time for this, and what type of listing which is most suitable.


Lytix Biopharma is developing next generation cancer treatment: Immunotherapy. If we succeed, Lytix Biopharma's technology could change the way we treat cancer.

Our technology is based on the exploitation of nature's own defense mechanisms. Bacteria and cancer cells are destroyed in a quick and efficient manner.

Record changed: 2017-08-28


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Lytix Biopharma AS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top